|
|
Abstract
IMMUNOGENICITY AND PROTECTIVE EFFICACY OF A PRIME BOOST STRATEGY USING DNA-MVA HIV/SIV VACCINES IN MACAQUES.
BIBERFELD G, MÄKITALO B, SUTTER G, TEN HAAFT P, WAHREN B, THORSTENSSON R
Aim: To investigate the immunogenicity and protective efficacy of a prime boost strategy using DNA-MVA HIV/SIV vaccines were explored in cynomolgus monkeys.
Methods: DNA expressing HIV-1IIIBenv, gag, pol, rev, tat and nef and MVA expressing HIV-1IIIBnef, tat and rev and SIVmacJ5gag/pol and vaccinia HIV-1env were used as immunogens. Four monkeys were immunized with 500µg of each DNA intramuscularly (im) at 0 and intrarectally (ir) and intraorally (io) at 2 months, followed by 108 pfu of each MVA-HIV/SIV im at 4 and ir and io at 8 months. Another group of four monkeys was immunized with the same immunogens im at 0, 2, 4 and 8 months. The vaccinated animals together with four monkeys immunized with control plasmids and MVA vector and four naive controls were challenged intravenously with 10 MID50 of SHIV-4 (HIV-1IIIB env, tat, rev) one month after the last MVA boost.
Results: All monkeys showed T cell proliferative responses after vaccination, while the ELISA antibody levels were low or undetectable. The highest cellular immune responses were demonstrated among the animals vaccinated mucosally. One animal, immunized mucosally and exhibiting the highest levels of HIV Env and Tat antibodies, CTL, and high T cell proliferative responses at the day of challenge, was completely protected against SHIV challenge. All the other seven vaccinated monkeys and the eight control animals became infected. However, at 4 weeks after challenge none of the four monkeys vaccinated mucosally and only two of four animals immunized im had detectable plasma viral RNA while all control animals had demonstrable viral RNA.
Conclusions: Combination of DNA and MVA-based multicomponent HIV/SIV vaccines induced stronger cellular immune responses and more effective control of challenge virus replication when administered intramuscularly and mucosally than when given intramuscularly only.
The 1st. IAS Conference on HIV Pathogenesis and Treatment
Abstract no.
10
Suggested Citation
"BIBERFELDG, et al.
IMMUNOGENICITY AND PROTECTIVE EFFICACY OF A PRIME BOOST STRATEGY USING DNA-MVA HIV/SIV VACCINES IN MACAQUES..
Oral Presentation:
The 1st. IAS Conference on HIV Pathogenesis and Treatment
:
Abstract no.
10"
|
|
|